Dry Your Tears

February is in the books and spring is right around the corner.  There are plenty of reasons to be upbeat if you suffer from the winter blahs, the least of which is we are close to record highs on all major indexes.

There is more to TearLab Corporation (NASDAQ – TEAR - $5.92) than a very catchy ticker symbol.  The ophthalmic device company engages in developing and marketing the TearLab Osmolarity System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease.  This system allows ocular professionals to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care.  Its innovative TearLab Osmolarity System consists of TearLab disposable which is made of a single-use microfluidic microchip.  Then there is the TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, which is a small desktop unit that allows for the docking of the TearLab disposable and the TearLab pen, as well as provides a quantitative reading for the operator.  The company operates in North America, Europe, and Asia.

TearLab is operating in the red as most of the small cap stocks in this space are due to the start up costs and time required for market penetration.  The Company has deployed a nationwide marketing campaign and sales force along with an aggressive pricing strategy.  Once TEAR completes this initial phase it should be poised to generate positive income due to the high barriers of entry in this business and related maintenance and service contracts. 

The stock hit a 52-week high yesterday mid-session of $6.04 before closing at $5.92.  The chart indicates a solid momentum play with a climb from a depth of $3.00 last June and a very bullish signal related to the short term EMA.  The stock averages over 150,000 trades per day with a few high volume sessions approaching half a million shares trades since the start of 2013.  There seems to be some gradual accumulation here.

TEAR is slated to release financials on March 20.  If then news illustrates continued progress, we see the stock possibly reaching $7 in 2Q13 as sales could grow by 300% or more in 2013. 

Have a great day!

Disclosure: Goldman Small Cap Research analysts are neither long nor short these shares but may elect to purchase the stock within the next 48 hours. 

Disclaimer:

This Market Monitor blog was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research, which typically highlights small cap companies, and Goldman Opportunity Research, which features micro cap companies in a sponsored research format. Thus, the Select product reflects the Firm’s internally generated stock ideas while the Opportunity product reflects sponsored research reports.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com